Corona Foot & Ankle Group launches new diabetic wound care approach

Corona Foot & Ankle Group in Corona is using an FDA-cleared ultrasound therapy and whole-foot care to treat diabetic foot wounds without surgery. The practice says the Medicare-covered program is helping Inland Empire patients heal faster and avoid amputations. Why it matters: - Diabetic foot wounds can lead to infection, prolonged disability and, in some cases, preventable amputation. - Corona Foot & Ankle Group is pitching a more complete treatment model for Inland Empire patients who have not healed with standard wound care. - The practice says the approach is designed to help patients keep walking and regain day-to-day mobility. What happened: - Corona Foot & Ankle Group introduced UltraMist, an FDA-cleared therapy for diabetic foot wounds. - The treatment uses gentle ultrasound energy, takes about three minutes per session and does not require surgery or needles. - The therapy is given two to three times a week. - The practice says results are already being seen in patients at its Corona office. - Medicare covers UltraMist automatically for eligible patients. - PPO patients receive pre-authorization after a wound has not improved significantly after four weeks. The details: - Dr. Arti Amin, the practice’s lead physician, said she has spent more than 26 years treating diabetic foot wounds and has reversed amputation recommendations. - Dr. Amin said patients who were told they had no more options often arrive exhausted and scared. - Diabetic foot wounds are difficult to treat because reduced circulation, nerve damage and weakened immunity can keep small cuts from closing. - About 90% of diabetic wounds occur on the foot. - Corona Foot & Ankle Group says its protocol looks beyond closing the wound and focuses on why the wound formed in the first place. - Infection analysis uses DNA sequencing to identify the bacteria present and match the antibiotic more precisely than a standard swab. - In-house X-rays provide same-visit screening for bone infection. - Liposana, an injectable tissue restoration treatment, is used for patients who have lost natural cushioning under the foot. - The practice says Liposana results can last one to two years. - Corona Foot & Ankle Group accepts Medicare and most PPO plans. - The practice provides insurance verification before the first appointment. - Patients with diabetic foot wounds or non-healing ulcers can reach the practice at coronafootandankle.com or (951) 444-5327. Between the lines: - The treatment is being framed as part of a broader limb-preservation strategy, not a stand-alone wound fix. - By combining podiatric care, vascular coordination and infection workups, the practice is signaling a more specialized model than many general wound centers. - Dr. Amin’s comments point to a key gap in diabetic care: patients often need clearer explanations of why wounds keep returning. What’s next: - Corona Foot & Ankle Group is likely to continue using UltraMist alongside its broader wound-care protocol for patients with chronic diabetic ulcers. - The practice says it will coordinate with vascular surgeons, interventional radiologists and infectious disease specialists when wounds require more than podiatric treatment. - Patients with complex wounds may be routed into the practice’s limb-salvage pathway rather than standard wound-only care. The bottom line: - Corona Foot & Ankle Group is betting that faster wound healing comes from treating the whole foot, not just the open sore.